Paxidep CR 37.5 is a generic controlled-release paroxetine tablet from the SSRI family, formulated to deliver a steady release of medication throughout the day. It enhances serotonin levels in the brain, which plays a critical role in mood regulation and anxiety management. The controlled-release mechanism helps reduce side effects and improves treatment adherence in patients dealing with complex psychiatric disorders.

- Sleep & Mental Health > Depression, Anxiety, PTSD This medication is effective in treating major depressive disorder (MDD), generalized anxiety disorder (GAD), panic disorder, and post-traumatic stress disorder (PTSD). It provides emotional balance and helps regulate stress responses. > Obsessive-Compulsive Disorder (OCD) Paxidep CR 37.5 is FDA-approved for OCD treatment, reducing obsessive thoughts and compulsive behaviors by modulating serotonin levels. > Panic Disorder It is prescribed to reduce panic attack frequency and severity and is a primary treatment option for preventing recurrence in panic disorder patients.

Paroxetine works by selectively inhibiting the serotonin reuptake transporter, increasing serotonin availability in the synaptic cleft. This mechanism restores neurotransmitter balance, which alleviates symptoms of depression, anxiety, and related disorders.

Adult Dosing - Depression & Major Depressive Disorder (MDD): Immediate Release (IR): Start at 20 mg daily, maintain 20–50 mg, max 50 mg Controlled Release (CR): Start at 25 mg daily, maintain 25–62.5 mg, max 62.5 mg Dose increases of 10 mg (IR) or 12.5 mg (CR) weekly. Treatment duration usually several months with efficacy demonstrated up to one year. - Social Anxiety Disorder (SAD): IR: Start 20 mg daily, maintain 20–60 mg, max 60 mg CR: Start 12.5 mg daily, maintain 12.5–37.5 mg, max 37.5 mg Treatment generally up to 12 weeks with weekly dose titration. - Panic Disorder (PD): IR: Start 10 mg daily, maintain 10–40 mg, max 60 mg CR: Start 12.5 mg daily, maintain 12.5–75 mg, max 75 mg Treatment duration usually up to 12 weeks; dose increments weekly. - Premenstrual Dysphoric Disorder (PMDD): CR only, dosing between 12.5–25 mg daily, either continuous or cyclic regimen. Recommended treatment spans at least 3 menstrual cycles; weekly dose increases possible. - Obsessive Compulsive Disorder (OCD): IR: Start 20 mg daily, maintain 20–60 mg, max 60 mg Requires long-term treatment with weekly dose increases of 10 mg. - Post-Traumatic Stress Disorder (PTSD) & Generalized Anxiety Disorder (GAD): IR: Start 20 mg daily, maintain 20–50 mg, max 50 mg Treatment typically lasts 12 weeks, with dose increments weekly. - Postmenopausal Symptoms: Mesylate capsules at 7.5 mg daily, indicated solely for vasomotor symptom relief. Geriatric Dosing: - Begin at lower doses (around 10 mg daily) with maintenance doses up to 40 mg for OCD, PTSD, SAD, GAD, PD, and depression. - Dose increases should be gradual and monitored closely because elderly patients have increased sensitivity. - Avoid use for mild or short-term anxiety related to everyday stress.

Store Paxidep CR 37.5 tablets in a tightly sealed container, kept in a cool, dry, and dark place away from moisture and direct sunlight. Avoid exposure to heat and humidity to maintain drug integrity. Keep out of reach of children and pets to prevent accidental ingestion.

Common side effects include nausea, dizziness, headache, insomnia, dry mouth, sweating, fatigue, and sexual dysfunction. Severe adverse effects might involve serotonin syndrome, bleeding tendencies, and withdrawal symptoms if stopped abruptly. Patients should be monitored regularly, and dosage adjustments should be made based on clinical response and tolerability.